The volume and pace of cancer research continues to accelerate, leading to substantial improvements in patient survival and quality of life.
As a result, the increased demand for anticancer drugs has led to significant growth for highly potent active pharmaceutical ingredients (HPAPIs).
However, HPAPIs present specific manufacturing and handling challenges. A unique know-how and dedicated corporate culture is required to safely manufacture HPAPIs, involving highly-skilled employees working in specialized facilities equipped with high-containment technologies.
Innovators often look to outsource HPAPIs, as CDMOs, such as Novasep, have the capabilities and expertise required.
> How process robustness and characterization lead to 100% compliant batches
> The value of the operational excellence program put in place to support commercial needs
> The deliverables obtained